Stockreport

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com
PDF - CX-801 is a dually masked, conditionally activated IFNa2b cytokine designed using the CytomX Probody® Therapeutic Platform -                   - Phase 1 first-in-huma [Read more]